CN105919136A - 一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法 - Google Patents
一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法 Download PDFInfo
- Publication number
- CN105919136A CN105919136A CN201610337135.6A CN201610337135A CN105919136A CN 105919136 A CN105919136 A CN 105919136A CN 201610337135 A CN201610337135 A CN 201610337135A CN 105919136 A CN105919136 A CN 105919136A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- preparation
- health food
- supplement composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 230000036039 immunity Effects 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 230000000694 effects Effects 0.000 title abstract description 20
- 235000016709 nutrition Nutrition 0.000 title abstract description 6
- 230000035764 nutrition Effects 0.000 title abstract description 6
- 239000013589 supplement Substances 0.000 title abstract 3
- 239000000284 extract Substances 0.000 claims abstract description 52
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 37
- 239000005017 polysaccharide Substances 0.000 claims abstract description 37
- 150000004676 glycans Chemical class 0.000 claims abstract description 35
- 241000005787 Cistanche Species 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 210000000582 semen Anatomy 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 16
- 240000002900 Arthrospira platensis Species 0.000 claims description 16
- 235000009392 Vitis Nutrition 0.000 claims description 16
- 241000219095 Vitis Species 0.000 claims description 16
- 229940082787 spirulina Drugs 0.000 claims description 16
- 244000241838 Lycium barbarum Species 0.000 claims description 15
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000007888 film coating Substances 0.000 claims description 6
- 238000009501 film coating Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 2
- 235000021286 stilbenes Nutrition 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 10
- 230000036541 health Effects 0.000 abstract description 9
- 230000029087 digestion Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 241001061264 Astragalus Species 0.000 abstract description 4
- 235000006533 astragalus Nutrition 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 240000008397 Ganoderma lucidum Species 0.000 abstract description 3
- 235000001637 Ganoderma lucidum Nutrition 0.000 abstract description 3
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 3
- 244000042430 Rhodiola rosea Species 0.000 abstract description 3
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract description 3
- 229940087603 grape seed extract Drugs 0.000 abstract description 3
- 235000002532 grape seed extract Nutrition 0.000 abstract description 3
- 239000001717 vitis vinifera seed extract Substances 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 230000035790 physiological processes and functions Effects 0.000 abstract description 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- -1 phenol glycoside Chemical class 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000031975 Yang Deficiency Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 210000004233 talus Anatomy 0.000 description 3
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000336291 Cistanche deserticola Species 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010006464 Hemolysin Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- RUDVAOJNIYYYCQ-HUIKYQPJSA-N (1S,2R,5R,7S,10R,11R,14R,15S,16S,18R,20S)-2,6,6,10,16-pentamethyl-18-(2-methylprop-1-enyl)-19,21-dioxahexacyclo[18.2.1.01,14.02,11.05,10.015,20]tricosane-7,16-diol Chemical compound CC(C)=C[C@H]1C[C@](C)(O)[C@@H]2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@@]33CO[C@@]2(C3)O1 RUDVAOJNIYYYCQ-HUIKYQPJSA-N 0.000 description 1
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MQDZZCJYWRZONM-UHFFFAOYSA-N Cistanoside A Natural products COc1ccc(CCOC2OC(COC3OC(CO)C(O)C(O)C3O)C(OC(=O)C=Cc4ccc(O)c(O)c4)C(OC5OC(C)C(O)C(O)C5O)C2O)cc1O MQDZZCJYWRZONM-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000006487 Euryale ferox Nutrition 0.000 description 1
- 244000268590 Euryale ferox Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000218300 Liriodendron Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- 206010038468 Renal hypertrophy Diseases 0.000 description 1
- 241001165494 Rhodiola Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010065954 Stubbornness Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229920006221 acetate fiber Polymers 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- RUDVAOJNIYYYCQ-UHFFFAOYSA-N jujubogenin Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)(O)CC(C=C(C)C)OC33OCC21C3 RUDVAOJNIYYYCQ-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000008627 kidney hypertrophy Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法,属于保健食品技术领域。包括有按重量份计的如下组分:肉苁蓉100~150份、灵芝多糖35~40份、葡萄籽提取物50~70份、枸杞子多糖35~45份、黄芪提取物45~55份、红景天提取物70~80份、螺旋藻多糖70~80份。本发明提供的组合物及其制剂能营养调整和平衡恢复生理机能,能从细胞层面上去满足身体对基础营养的需求,使人体基因维持健康状态,从而达到平衡代谢,增强机体免疫力,延缓衰老、抗疲劳,提高消化吸收功能等。
Description
技术领域
本发明涉及一种具有营养补充剂组合物、及药物剂型和制备方法,更具体的是涉及一种具有抗疲劳和提高免疫力的营养补充剂,属于保健食品技术领域。
背景技术
一般人常常认为,人只有健康和患病之分。但新的医学研究表明,人体健康与患病之间还存在着一个过渡的中间状态,即第三状态。亚健康状态(subhealth)也称“第三状态”、“灰色状态”。 亚健康状态是身体处于健康和疾病之间的一种临界状态,一般是指机体无明显的疾病,却表现出活力降低,各种适应能力不同程度的减退。亚健康状态是一种新医学思维,标志着人们随着生活质量的提高,对健康的要求更加深入。亚健康具体可有多种表现,如疲乏无力、睡眠障碍、焦虑抑郁、头痛头晕、记忆力下降、经常易感冒、周身酸痛不适等,可归结为躯体、精神心理及社交三个方面。
医学上所说的免疫力,它是人体免疫系统进行自我保护的一种能力,主要的任务之一是身体抵抗细菌或病毒等感染的能力,免疫系统是一个由许多环节共同发挥作用的系统,不同环节起到不同的作用,人的免疫力有一部分是与生俱来的,另外一部分则需要经过后天不断完善、成熟。医学上认为,摆脱顽固的慢性疾病,关键是要调动起自身的免疫力,充分利用免疫调节,可以使人的身体树立起天然的抗病屏障。我们所说的免疫力,是指机体识别和排除抗原性异物的功能,即机体区分自己和非己的功能。威胁人类健康的许多疾病都与人体的免疫力紧紧相关。这是因为,人体免疫系统可辨别身体自己的细胞和外来的侵略物质,例如细菌和病毒等,并设法排斥或消灭入侵的细菌和病毒。人体的免疫功能与细菌和病毒仿佛处于天平的两端,免疫力增强,细菌和病毒就无从作怪,然而只要人体的免疫力下降,这些在人体内蠢蠢欲动的细菌和病毒就开始兴风作浪,因此提高免疫力也成为防病抗病的关键手段。
CN103494203B公开一种具有增强免疫力功能的保健食品,原料重量配比如下:硒化卡拉胶1-10份,薏苡仁提取物50-150份,蒲公英提取物100-200份,维生素E 10-100份。还含有芡实提取物1-40份,麦绿素50-150份;公开(公告)号: CN103750104B公开一种综合改善脾胃肠道不适症的保健食品及其制备方法,食品特征由以下重量份数制备:低聚半乳糖0.1–5,低聚果糖0.5–6,聚葡萄糖0.5–8,山药提取物0.1–1.5,麦芽0.1–2.5,红枣0.5–3。制备特征①取麦芽和红枣,进行除杂→冲洗→烘干→研磨成60–80目细粉;②将步骤①细粉与低聚半乳糖、低聚果糖、低聚葡萄糖和山药提取物一起均匀混合;③将混合后的混合细粉,用浓度90–95%的食用酒精对混合细粉进行制粒;④将颗粒物经60–75℃灭菌1–1.5小时;⑤将灭菌后的颗粒物过60–80目筛,装入复合铝膜袋内保存,即为成品。
上述的保健食品存在着功能单一、保健作用不明显的问题,因此,有必要提供一种较好的保健食品组合物。
发明内容
本发明的目的是:提供一种具有抗疲劳和提高免疫力的营养补充剂、及药物剂型和制备方法。
技术方案:
一种具有抗疲劳提高免疫力作用的营养补充剂组合物,包括有按重量份计的如下组分:
肉苁蓉(Cistanche Deserticola)100~150份、灵芝多糖(Ganoderma Lucidum)35~40份、葡萄籽提取物(Grape Seed Extract)50~70份、枸杞子多糖(Barbary Wolfberry)35~45份、黄芪提取物(Radix Astragalus)45~55份、红景天提取物(Rhodiola Rosea)70~80份、螺旋藻多糖(Spirulina Polysaccharide)70~80份。
在一个优选实施例中,肉苁蓉125份、灵芝多糖37.5份、葡萄籽提取物60份、枸杞子多糖40份、黄芪提取物50份、红景天提取物75份、螺旋藻多糖75份。
含有上述营养补充剂组合物的保健食品。
所述的保健食品的剂型是片剂。
在片剂中,所述的营养补充剂组合物中还包括有微粉硅胶90~95份,硬脂酸镁2.0~2.5份。
所述的微粉硅胶是92.5份,所述的硬脂酸镁是2.3份。
所述的片剂的制备方法,包括如下步骤:将肉苁蓉、灵芝多糖、葡萄籽提取物、枸杞子多糖、黄芪提取物、红景天提取物、螺旋藻多糖粉配比混匀,粉碎后过80目筛,加微粉硅胶,混匀,用70vol.% 乙醇制成软材,通过18目筛制粒,干燥、整粒,再加入硬脂酸镁,混匀,压片,包薄膜衣。
所述的70vol.% 乙醇的用量是药粉重量的20%。
所述的干燥步骤的温度是60℃。
有益效果
本发明提供的组合物及其制剂能营养调整和平衡恢复生理机能,能从细胞层面上去满足身体对基础营养的需求,使人体基因维持健康状态,从而达到平衡代谢,增强机体免疫力,延缓衰老、抗疲劳,提高消化吸收功能等。
具体实施方式
本发明所提供的组合中包括有以下的组分:肉苁蓉(Cistanche Deserticola)100~150份、灵芝多糖(Ganoderma Lucidum)35~40份、葡萄籽提取物(Grape Seed Extract)50~70份、枸杞子多糖(Barbary Wolfberry)35~45份、黄芪提取物(Radix Astragalus)45~55份、红景天提取物(Rhodiola Rosea)70~80份、螺旋藻多糖(SpirulinaPolysaccharide)70~80份。
其中,肉质茎含肉苁蓉甙A、B、C、H,洋丁香酚甙、2-乙酰基洋丁香酚甙、海胆甙七种苯乙醇甙成分,还含鹅掌楸甙、8-表马钱子甙酸、胡萝卜甙、甜菜碱、β-谷甾醇、甘露醇,N,N-二甲基甘按酸甲酯和苯丙氨酸、缬氨酸、亮氨酸、异亮氨酸、赖氨酸、苏氨酸等十五种氨基酸及琥珀酸、三十烷醇、多糖类。补肾阳;益精血;润肠道。
灵芝多糖有多方面的药理活性:能提高机体免疫力,加速血液微循环,提高血液供氧能力,降低机体静止状态下的无效耗氧量,消除体内自由基,提高机体细胞膜的封闭度,抗放射,提高肝脏、骨髓、血液合成 DNA,RNA,蛋白质的能力,延长 寿命等。
葡萄籽提取物是迄今发现的植物来源的最高效的抗氧化剂之一,体内和体外试验表明,葡萄籽提取物“原花青素OPC”的抗氧化效果,是维生素C和维生素E的50-70倍。超强的抗氧化效率具有清除自由基、提高人体免疫力的强力效果。
枸杞子多糖是淡黄色纤维状固体,有调节免疫、延缓衰老多种功效,可制药。
黄芪提取物具有增强免疫力,增强能量,抗疲劳,抗突变,保肝,抑制破骨细胞的作用。黄芪多糖具有降血脂,即降低胆固醇和甘油三酯、升高高密度脂蛋白的作用;能够预防和治疗心脑血管疾病,如动脉粥样硬化、冠状动脉病变、周围血管病变以及高脂血症等。黄芪甲苷具有显著降低血糖、糖化血红蛋白和尿蛋白的作用,可降低肾皮质和血清中的AGEs,显示黄芪甲苷具有抗氧化作用,并对醛糖还原酶有抑制作用,还有抑制系膜细胞增生、减轻肾脏肥大的作用。
红景天有补气清肺、益智养心、收涩止血、散瘀消肿的功效。红景天提取物主要成份为红景天苷和甙元酪醇、络塞维,具有增强免疫功能、保护心脑血管及抗癌抗抑郁的功效。为行补气清肺的要药;与肉苁蓉配伍一升一降,功可调畅精血。
螺旋藻多糖是从螺旋藻中提取的多糖类化合物,具有抗肿瘤、抗辐射、促进DNA合成及免疫增强作用。近年来有众多文献报道螺旋藻可作为肝炎、糖尿病、胃溃疡的辅助治疗,所有这些作用均有利于提高机体的抗病能力,特别是其免疫增强作用,将有利于机体的延缓衰老作用。 螺旋藻多糖具有免疫增强,改善造血功能及促进蛋白质合成的作用,这一作用也可能是其抗衰老的重要原国之一。
上述葡萄籽提取物、红景天提取物和黄芪提取物可以通过将原料葡萄籽、红景天和黄芪浸渍于溶剂并提取后进行过滤、 减压及浓缩后获取的浓缩物。上述溶剂可以是水、C1~C4的无水或含水酒精、醋酸纤维、丙三醇、丙二醇及丙烯二醇中的一个或多种的混合物,但不限于此。提取可以通过室温静置来进行,但能够根据需要通过加热、搅拌、加热回流来促进提取。所得的提取液可以直接使用,或实施适当过滤、浓缩、脱色等处理后使用。此外,也能够在暂时除去溶剂之后,在与提取所用的溶剂不同的溶剂中进行再溶解后使用。还能够将所得的提取物通过活性炭、柱色谱等进一步纯化后使用。
本发明的以上组成中,如果以克为单位,上述配方组成可制成一个疗程剂量的药物制剂,若日服2-4次,为20-40天的服用量,如制成制剂,则因制剂的大小不同可制成100-1000剂。所述100-1000剂是指单位剂量的制剂形式,如片剂100-1000片,胶囊剂100-1000粒,颗粒剂l00-1000份,口服液l00-l000ml,膏剂l00-l000份,丸剂10-1000丸等。
以上组成是按重量作为配比的,在生产时可按照相应比例增大或减少,如大规模生产可以以kg为单位,或以t(吨)为单位;小规模制剂也可以以g为单位。重量可以增大或者减小,但各组成之间的生药材重量配比的比例不变。
以上重量配比的比例是经过科学筛选得到的,对于特殊病人,如重症或轻症,肥胖或瘦小的病人,可以相应调整组成的量的配比,增加或减少不超过100%,药效基本不变。
本发明的组合物,优选的是单位剂量的制剂形式,在制成制剂时可以制成任何可药用的剂型,这些剂型选自:片剂、胶囊剂、口服液、口含剂、颗粒剂、丸剂、散剂、膏剂、丹剂、优选的是口服制剂形式,最优选的是丸剂,片剂,胶囊剂,颗粒剂。
本发明的组合物,根据需要可以加入一些药物可接受的载体,可以采用制剂学常规技术制备该药物制剂,如将药物活性物质与药物可接受的载体混合。所述药物可接受的的载体选自:蜂蜜、练蜜、甘露醇、山梨醇、山梨酸或钾盐、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素A、维生素C、维主素E、维生素D、氮酮、EDTA二钠、EDTA钙钠,一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、丙二醇、乙醇、土温60-80、司班-80、蜂蜡、羊毛脂、液体石蜡、十六醇、没食子酸酯类、琼、三乙醇胺、碱性氨基酸、尿素、尿囊素、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、B-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的制剂,在制成药剂时,单位剂量的药剂可含有本发明的药物活性物质0.1~l000mg,其余为药学上可接受的载体。药学上可接受的载体以重量计可以是制剂总重量的0. 01-99. 9%。
本发明的药物制剂在使用时根据病人的情况确定用法用量。服用方法因病人的体质情况对症服用,如日服1-4次,每次1-4丸。
实施例1
将肉苁蓉125g、灵芝多糖37.5g、葡萄籽提取物60g、枸杞子多糖40g、黄芪提取物50g、红景天提取物75g、螺旋藻多糖粉75g按上述配比混匀,粉碎后过80目筛,加微粉硅胶92.5g,混匀,用70% 乙醇制软材(用量约为药粉量的 20%),18目筛制粒,60℃干燥,整粒,加入硬脂酸镁2.3g,混匀,压片,包薄膜衣,制成5000片,每片约0.11g。
对照例1
与实施例1的区别在于:组分中未加入葡萄籽提取物。
将肉苁蓉125g、灵芝多糖37.5g、枸杞子多糖40g、黄芪提取物50g、红景天提取物75g、螺旋藻多糖粉75g按上述配比混匀,粉碎后过80目筛,加微粉硅胶92.5g,混匀,用70%乙醇制软材(用量约为药粉量的 20%),18目筛制粒,60℃干燥,整粒,加入硬脂酸镁2.3g,混匀,压片,包薄膜衣,制成5000片,每片约0.11g。
对照例2
与实施例1的区别在于:组分中未加入枸杞子多糖。
将肉苁蓉125g、灵芝多糖37.5g、葡萄籽提取物60g、黄芪提取物50g、红景天提取物75g、螺旋藻多糖粉75g按上述配比混匀,粉碎后过80目筛,加微粉硅胶92.5g,混匀,用70%乙醇制软材(用量约为药粉量的 20%),18目筛制粒,60℃干燥,整粒,加入硬脂酸镁2.3g,混匀,压片,包薄膜衣,制成5000片,每片约0.11g。
对照例3
与实施例1的区别在于:组分中未加入红景天提取物。
将肉苁蓉125g、灵芝多糖37.5g、葡萄籽提取物60g、枸杞子多糖40g、黄芪提取物50g、螺旋藻多糖粉75g按上述配比混匀,粉碎后过80目筛,加微粉硅胶92.5g,混匀,用70%乙醇制软材(用量约为药粉量的 20%),18目筛制粒,60℃干燥,整粒,加入硬脂酸镁2.3g,混匀,压片,包薄膜衣,制成5000片,每片约0.11g。
药效试验
一、耐缺氧实验,抗疲劳实验、耐高温实验
本实验是根据常用的抗应激实验,对服用了本发明所述的组合物的疲劳饥饿小鼠进行观察。主要实验为:耐缺氧实验,抗疲劳实验、耐高温实验。
1试药与材料
1.1实验对象:昆明种老龄小鼠(10月龄),体重45~55g,雌性。
1.2受试样品:
受试样品1:为上述实施例1的片剂。
受试样品2:为上述对照例1的片剂。
受试样品3:为上述对照例2的片剂。
受试样品4:为上述对照例3的片剂。
在本文中,片剂用于药效试验时,需要经过先研磨混合均匀处理。
1.3分组与给药
随机分为5组,每组12只,其分别为空白对照组(正常组)和受试样品1、2、3、4组。上述分别按人剂量3.0g/kg为小鼠用剂量加适量水溶解灌胃使用。各组动物在实验过程中自由饮用0.1%BSA酸化水,空白组每日灌服生理盐水,其它4组分别灌服受试样品,每日1次,连续4周。
2方法与结果
2.1对小鼠常压缺氧耐力的影响末次给药前饥饿16h,末次给药后1h将小鼠放入盛有10g钠石灰的250ml广口瓶中,加盖凡士林密封,记录小鼠生存时间。结果见下表1。
2.2对小鼠抗疲劳作用的影响末次给药前饥饿24h,末次给药后1h将小鼠放入27±2℃水池中,记录小鼠在水中生存时间(记录小鼠入水至口鼻沉入水下达10s以上时间)。结果见下表1。
2.3耐高温试验末次给药后1h将小鼠放入75±1℃恒温箱中,记录生存时间。结果见下表1。
表1抗应激试验结果表(n=10)
级别 | 抗缺氧(秒) | 抗疲劳(秒) | 抗高温(秒) |
空白对照组 | 3747±328* | 1222±232* | 374±13* |
受试样品1(实施例1) | 4157±458 | 1556±162 | 424±25 |
受试样品2(对照例1) | 3612±511 | 1258±325# | 369±75 |
受试样品3(对照例2) | 3508±355 | 1389±225# | 394±32 |
受试样品4(对照例3) | 3133±374 | 1379±287# | 385±31 |
*P<0.05,空白对照组与各组比较;#P<0.05,受试样品与受试样品1比较。
结果表明,抗缺氧、抗疲劳、抗高温等三项指标中,空白对照组与各组之间有显著性差异,说明该组合物能增加老龄小鼠耐缺氧、耐疲劳、耐高温的存活时间。 实施例1相对于对照例1来说,加入了葡萄籽提取物,与其它药物协同作用后,可以提高小鼠的抗疲劳的机能。
二、提高免疫力
A、对免疫功能的影响
1.对小鼠腹腔巨噬细胞吞噬功能的影响
取小鼠60只,体重19~23g,♂♀各半,随机分6组:空白对照组、阴性对照组(左旋咪唑)及4个药组(实施例1、对照例1~3,3g/kg),按体重灌胃给药或N.S,每天给药一次,连续给药7天,末次给药后1小时每鼠腹腔注射2%鸡红细胞悬液1ml,2小时后脱颈椎处死动物,仰位固定鼠板上,腹腔注入2mlN.S,转动鼠板,然后吸出腹腔液1ml,平均滴于两片玻片上,放入垫有湿布的盘内,在37℃孵箱温育30分钟后,染色,求吞噬百分率及指数。结果见下表:
本发明制剂对小鼠腹腔巨噬细胞吞噬功能的影响(n=10, X±S)
组别 | 剂量 g/kg | 吞噬百分率 | P值 | 吞噬指数 | P值 |
空白对照组 | 35.11±5.53 | 0.33±0.11 | |||
左旋咪唑 | 0.04 | 52.36±4.37 | <0.01 | 0.51±0.04 | <0.01 |
实施例1 | 3.0 | 55.81±5.35 | <0.01 | 0.52±0.05 | <0.01 |
对照例1 | 3.0 | 46.27±3.24 | <0.01 | 0.45±0.03 | <0.01 |
对照例2 | 3.0 | 41.34±4.22 | <0.01 | 0.44±0.02 | <0.01 |
对照例3 | 3.0 | 44.75±4.95 | <0.01 | 0.45±0.01 | <0.01 |
从上表可知,本发明制剂能明显地增加巨噬细胞的吞噬功能。
2.对血清溶血素含量(HC50)的影响取小鼠60只,体重19~23g,♂♀各半,随机分6组:分组、给药途径及给药剂量同上述实验。每天给药1次,连续给药8天。给药2天后,每鼠腹腔注射20%绵羊红细胞悬液0.2ml致敏,致敏6天后,摘眼球取血1ml,2小时后离心分离血清,按照《药理实验方法学》中测血清溶血素含量(HC50)的要求进行,结果见下表:
本发明制剂对小鼠血清溶血素含量(HC50)的影响(n=10,X±S)
组别 | 剂量 g/kg | HC50 | P值 |
空白对照组 | 52.34±17.11 | ||
左旋咪唑 | 0.04 | 90.68±18.55 | <0.01 |
实施例1 | 3.0 | 102.58±18.15 | <0.01 |
对照例1 | 3.0 | 85.82±12.68 | <0.01 |
对照例2 | 3.0 | 82.57±11.28 | <0.01 |
对照例3 | 3.0 | 78.38±10.17 | <0.01 |
实验结果表明, 本发明制剂能显著增加血清溶血素的含量。实施例1相对于对照例3来说,加入了红景天提取物,与其它药物协同作用后,可以提高小鼠的血清溶血素含量。
三、对阳虚症小鼠的影响
取雄性小鼠60只,体重20~23g,将小鼠随机分6组:正常对照组、阳虚证模型组(氢化可的松0.125g/kg)及氢化可的松+本发明制剂(实施例1、对照例1~3,3g/kg)4组。各组均灌胃给 药或N.S,每天一次,连续用药6天。给药第4天(除正常对照组外)同时肌注氢化可的松0.125g/kg,连续肌注3天。末次给药后1小时记录各组小鼠体重、体温、自主活动次数(10 分钟内)及低温游泳存活时间,结果见下表:
本发明制剂对阳虚证小鼠的影响(n=10, X±S)
注 : 与阳虚模型组比较 ※P < 0.05, ※※P < 0.01。
结果表明本药能使阳虚证小鼠体温升高,活动增加,低温游泳时间延长,体重增加。实施例1相对于对照例3来说,通过加入红景天提取物,提高了促进阳虚证小鼠恢复体力的效果。
三、促进消化的作用
实验动物
清洁级SD大鼠60只,雄性,体质量180g±20g,饲养于室温25℃,湿 度45%的环境,自然光照时间12h。随机分6组:正常对照组、阴性对照组(多潘立酮,0.2g/kg)及4个药组(实施例1、对照例1~3,3g/kg),按体重灌胃给药或N.S,每天给药一次,连续给药7天,大鼠体重变化:见下表。
造模结束时大鼠体重(n=10, X±S)
组别 | 样本数(N) | 大鼠体重变化 |
实施例1组 | 12 | 250.63±14.20* |
对照例1组 | 12 | 234.22±11.63* |
对照例2组 | 12 | 232.28±11.25* |
对照例3组 | 12 | 235.62±11.43* |
多潘立酮组 | 12 | 244.51±12.16* |
空白对照组 | 12 | 175.22±16.88 |
注:与空白组比较*P<0.05。
结果表明:实施例和对照例组以及多潘立酮组大鼠体重均增加,差异有统计学意义(P<0.05);说明对治疗功能性消化不良均有效。 实施例1相对于对照例2组来说,加入了枸杞子多糖与其它成分协同作用可以提到提高消化水平的作用。
2.2各组大鼠胃排空率比较:见下表
各组大鼠胃排空率比较 (n=10, X±S)
组别 | 样本数(N) | 胃排空率(%) |
实施例1组 | 12 | 68.53±10.26* |
对照例1组 | 12 | 59.55±3.25* |
对照例2组 | 12 | 55.88±5.88* |
对照例3组 | 12 | 57.32±5.21* |
多潘立酮组 | 12 | 61.32±5.21* |
空白对照组 | 12 | 45.56±7.31 |
注:与空白对照组比较,*P<0.05。
结果提示:与空白对照组比较,其余各组大鼠胃排空明显提高,差异有显著统计学意义(P<0.01);实施例1相对于对照例2组来说,加入了枸杞子多糖与其它成分协同作用可以提到提高消化水平的作用。
2.3各组小鼠胃组织NO、SCF含量的表达比较:见表6
表6各组大鼠血清NO、SCF含量比较(n=10, X±S)
组别 | 样本数(N) | NO含量(μmol/L) | SCF含量(μmol/L) |
实施例1组 | 12 | 0.11±0.12* | 34.96±2.60* |
对照例1组 | 12 | 0.15±0.08*▲ | 23.66±1.85* |
对照例2组 | 12 | 0.15±0.06*▲ | 24.19±2.98* |
对照例3组 | 12 | 0.18±0.09*▲ | 24.13±3.10* |
多潘立酮组 | 12 | 0.15±0.04* | 26.72±4.55* |
空白对照组 | 12 | 0.21±0.08* | 21.64±4.58 |
注:与空白对照组比较,*P<0.05。
结果提示: 经实施例治疗后,与空白组比较,大鼠血清SCF升高,而血清NO含 量降低,差异有统计学意义(P<0.05)。实施例1相对于对照例2组来说,加入了枸杞子多糖与其它成分协同作用可以提到提高消化水平的作用。
另外,以上实施例和对照例制备得到的片剂的检查结果如下:
实施例1 | 对照例1 | 对照例2 | 对照例3 | |
硬度 kgf | 8.26 | 8.22 | 8.26 | 8.11 |
脆碎度 % | 1.32 | 2.39 | 2.21 | 4.54 |
从表中可以看出,本发明制备的片剂具有较好的性状,实施例1相对于对照例2来说,通过加入了枸杞子多糖可以有效地降低片剂的脆碎度。
Claims (9)
1.一种具有抗疲劳提高免疫力作用的营养补充剂组合物,其特征在于:包括有按重量份计的如下组分:肉苁蓉100~150份、灵芝多糖35~40份、葡萄籽提取物50~70份、枸杞子多糖35~45份、黄芪提取物45~55份、红景天提取物70~80份、螺旋藻多糖70~80份。
2.根据权利要求1所述的具有抗疲劳提高免疫力作用的营养补充剂组合物,其特征在于:组分重量比是:肉苁蓉125份、灵芝多糖37.5份、葡萄籽提取物60份、枸杞子多糖40份、黄芪提取物50份、红景天提取物75份、螺旋藻多糖75份。
3.含有权利要求1所述的营养补充剂组合物的保健食品。
4.根据权利要求3所述的保健食品,其特征在于,剂型是片剂。
5.根据权利要求4所述的保健食品,其特征在于,在片剂中,所述的营养补充剂组合物中还包括有微粉硅胶90~95份,硬脂酸镁2.0~2.5份。
6.根据权利要求5所述的保健食品,其特征在于,所述的微粉硅胶是92.5份,所述的硬脂酸镁是2.3份。
7.权利要求4所述的保健食品的制备方法,其特征在于,所述的片剂的制备方法包括如下步骤:将肉苁蓉、灵芝多糖、葡萄籽提取物、枸杞子多糖、黄芪提取物、红景天提取物、螺旋藻多糖粉配比混匀,粉碎后过80目筛,加微粉硅胶,混匀,用70vol.% 乙醇制成软材,通过18目筛制粒,干燥、整粒,再加入硬脂酸镁,混匀,压片,包薄膜衣。
8.权利要求7所述的保健食品的制备方法,其特征在于,所述的70vol.% 乙醇的用量是药粉重量的20%。
9.权利要求7所述的保健食品的制备方法,其特征在于,所述的干燥步骤的温度是60℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610337135.6A CN105919136A (zh) | 2016-05-21 | 2016-05-21 | 一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610337135.6A CN105919136A (zh) | 2016-05-21 | 2016-05-21 | 一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105919136A true CN105919136A (zh) | 2016-09-07 |
Family
ID=56841868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610337135.6A Pending CN105919136A (zh) | 2016-05-21 | 2016-05-21 | 一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105919136A (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106473038A (zh) * | 2016-09-18 | 2017-03-08 | 天津北洋百川生物技术有限公司 | 一种肉苁蓉保健片及其制备方法 |
CN107198238A (zh) * | 2017-07-11 | 2017-09-26 | 丽江格林斯通食品有限公司 | 一种复方螺旋藻润肠美容片及其制备方法 |
CN107198007A (zh) * | 2017-05-23 | 2017-09-26 | 西安天丰生物科技有限公司 | 一种提神抗疲劳压片糖果及其制作方法 |
CN107397176A (zh) * | 2017-07-20 | 2017-11-28 | 明光市昊昊蜂业有限公司 | 一种龙眼蜂蜜 |
CN107937196A (zh) * | 2018-01-08 | 2018-04-20 | 吉林华兰德酒庄有限公司 | 一种用冰葡萄酿造干型酒的酿造方法 |
CN109331143A (zh) * | 2018-10-30 | 2019-02-15 | 河西学院 | 一种苁蓉复合物及其制法 |
CN112493487A (zh) * | 2020-11-27 | 2021-03-16 | 深圳市新靶向生物科技有限公司 | 一种增强人体免疫力的组合物及其制备方法和保健品 |
CN114982850A (zh) * | 2022-04-22 | 2022-09-02 | 齐鲁工业大学 | 一种枸杞菊花当归复合压片糖果及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003009813A (ja) * | 2001-07-03 | 2003-01-14 | Toyo Shinyaku:Kk | 健康食品 |
CN101283804A (zh) * | 2007-04-09 | 2008-10-15 | 宁小静 | 保健食品 |
CN102641325A (zh) * | 2012-04-25 | 2012-08-22 | 吉林大学珠海学院 | 一种具有抗疲劳、提高免疫力作用的保健品及制备方法 |
CN102872206A (zh) * | 2012-10-12 | 2013-01-16 | 中国医学科学院药用植物研究所云南分所 | 一种提高免疫力、抗疲劳、改善性功能的中药复合物 |
CN103637187A (zh) * | 2013-11-21 | 2014-03-19 | 威海五谷怡健食品有限公司 | 可增强人体免疫力、抗疲劳的保健食品及其制备方法 |
CN103800672A (zh) * | 2014-02-14 | 2014-05-21 | 安徽天马生物科技有限公司 | 一种缓解体力疲劳的保健胶囊及其制备方法 |
-
2016
- 2016-05-21 CN CN201610337135.6A patent/CN105919136A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003009813A (ja) * | 2001-07-03 | 2003-01-14 | Toyo Shinyaku:Kk | 健康食品 |
CN101283804A (zh) * | 2007-04-09 | 2008-10-15 | 宁小静 | 保健食品 |
CN102641325A (zh) * | 2012-04-25 | 2012-08-22 | 吉林大学珠海学院 | 一种具有抗疲劳、提高免疫力作用的保健品及制备方法 |
CN102872206A (zh) * | 2012-10-12 | 2013-01-16 | 中国医学科学院药用植物研究所云南分所 | 一种提高免疫力、抗疲劳、改善性功能的中药复合物 |
CN103637187A (zh) * | 2013-11-21 | 2014-03-19 | 威海五谷怡健食品有限公司 | 可增强人体免疫力、抗疲劳的保健食品及其制备方法 |
CN103800672A (zh) * | 2014-02-14 | 2014-05-21 | 安徽天马生物科技有限公司 | 一种缓解体力疲劳的保健胶囊及其制备方法 |
Non-Patent Citations (2)
Title |
---|
徐晓飞等: "植物多糖的保健功能及开发前景", 《中国食物与营养》 * |
楼凤昌 等: "《国家执业药师手册》", 30 November 2004, 清华大学出版社 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106473038A (zh) * | 2016-09-18 | 2017-03-08 | 天津北洋百川生物技术有限公司 | 一种肉苁蓉保健片及其制备方法 |
CN107198007A (zh) * | 2017-05-23 | 2017-09-26 | 西安天丰生物科技有限公司 | 一种提神抗疲劳压片糖果及其制作方法 |
CN107198238A (zh) * | 2017-07-11 | 2017-09-26 | 丽江格林斯通食品有限公司 | 一种复方螺旋藻润肠美容片及其制备方法 |
CN107397176A (zh) * | 2017-07-20 | 2017-11-28 | 明光市昊昊蜂业有限公司 | 一种龙眼蜂蜜 |
CN107937196A (zh) * | 2018-01-08 | 2018-04-20 | 吉林华兰德酒庄有限公司 | 一种用冰葡萄酿造干型酒的酿造方法 |
CN107937196B (zh) * | 2018-01-08 | 2021-01-15 | 吉林华兰德酒庄有限公司 | 一种用冰葡萄酿造干型酒的酿造方法 |
CN109331143A (zh) * | 2018-10-30 | 2019-02-15 | 河西学院 | 一种苁蓉复合物及其制法 |
CN109331143B (zh) * | 2018-10-30 | 2022-07-08 | 河西学院 | 一种苁蓉复合物及其制法 |
CN114887018A (zh) * | 2018-10-30 | 2022-08-12 | 河西学院 | 一种苁蓉复合物及其制法 |
CN112493487A (zh) * | 2020-11-27 | 2021-03-16 | 深圳市新靶向生物科技有限公司 | 一种增强人体免疫力的组合物及其制备方法和保健品 |
CN112493487B (zh) * | 2020-11-27 | 2022-10-25 | 深圳市新靶向生物科技有限公司 | 一种增强人体免疫力的组合物及其制备方法和保健品 |
CN114982850A (zh) * | 2022-04-22 | 2022-09-02 | 齐鲁工业大学 | 一种枸杞菊花当归复合压片糖果及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105919136A (zh) | 一种具有抗疲劳提高免疫力作用的营养补充剂组合物、制剂及其制备方法 | |
JP6305407B2 (ja) | 免疫を調節する漢方薬組成物及びその製造方法 | |
CN109674958B (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN104922176B (zh) | 一种野菊花提取物的应用 | |
CN105997985A (zh) | 一种大麻提取物在制备治疗痛风药物中的应用 | |
CN105832794A (zh) | 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用 | |
CN106074493A (zh) | 一种大麻提取物在制备治疗痛风性关节炎药物中的应用 | |
CN105055855B (zh) | 具有改善睡眠、增强免疫力作用的中药组合物及其制备方法和应用 | |
CN101474330B (zh) | 一种止泻口服液及其制备工艺 | |
CN1923256A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN103735621B (zh) | 一种具有降血脂和增强免疫力作用的中药组合物 | |
CN1814214A (zh) | 一种治疗体形消瘦、体质虚弱的中药组合物及其制备方法 | |
CN107537028B (zh) | 一种同时辅助降血糖及降血压的配方及其制备方法 | |
CN1313112C (zh) | 一种具有养神镇静作用的药物组合物 | |
CN107536016B (zh) | 一种保护心脏和促进肝脏健康的营养食品 | |
CN1768838A (zh) | 一种促进排铅的中药制剂及其制备方法 | |
CN103961431B (zh) | 一种提高动物免疫力的药物组合物 | |
CN103599259B (zh) | 一种具有降血糖作用的傣药提取物制备及其应用 | |
CN102743461A (zh) | 一种和胃安神的中药组合物、制备方法及其应用 | |
CN102784230A (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN105285977A (zh) | 一种具有抗衰老、提高免疫力功效的保健品 | |
CN104623352B (zh) | 一种改善睡眠的药物组合物 | |
CN103893512B (zh) | 一种治疗痛风性关节炎的中药组合物 | |
CN112057476B (zh) | 一种组合物及其在醒酒解宿醉护胃上的应用 | |
CN102327304A (zh) | 一种防治慢性高原病的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170630 Address after: 727007, No. five, Datang 6, South Industrial Park, New District, Shaanxi, Tongchuan Applicant after: SHAANXI FENGHE PHARMACEUTICAL CO., LTD. Address before: 727007 Tongchuan City, Shaanxi Province Road No. 15 Yintai district with Applicant before: Shaanxi Wang Jin Tao mentally Biological Technology Co. Ltd. |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160907 |